D. E. Shaw & Co., Inc. Atossa Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.28 $364,100 - $776,747	-606,834 Reduced 73.7%	216,528 $272,000
Q1 2023 May 15, 2023	SELL	$0.59 - $0.91 $383,950 - $592,194	-650,763 Reduced 44.15%	823,362 $592,000
Q4 2022 Feb 14, 2023	SELL	$0.5 - $1.01 $146,606 - $296,144	-293,212 Reduced 16.59%	1,474,125 $781,000
Q3 2022 Nov 14, 2022	SELL	$0.82 - $1.14 $420,085 - $584,020	-512,299 Reduced 22.47%	1,767,337 $1.47 Million
Q2 2022 Aug 15, 2022	SELL	$0.85 - $1.28 $1.35 Million - $2.03 Million	-1,583,499 Reduced 40.99%	2,279,636 $2.49 Million
Q1 2022 May 16, 2022	SELL	$1.11 - $1.74 $315,988 - $495,332	-284,674 Reduced 6.86%	3,863,135 $4.83 Million
Q4 2021 Feb 14, 2022	BUY	$1.6 - $3.27 $5.2 Million - $10.6 Million	3,251,752 Added 362.9%	4,147,809 $6.64 Million
Q3 2021 Nov 15, 2021	BUY	$2.89 - $6.4 $2.59 Million - $5.73 Million	896,057 New	896,057 $2.92 Million

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.